Osteoporosis and Fracture Risk in Aging

Osteoporosis is the most common metabolic bone disease in older adults, affecting an estimated 10 million Americans and contributing to approximately 1.5 million fractures annually (National Osteoporosis Foundation). Bone density loss accelerates after age 50, particularly in postmenopausal women, creating a silent progression that often goes undetected until a fracture occurs. This page covers the physiological mechanisms of bone loss, the clinical classification of fracture risk, the scenarios most frequently encountered in geriatric care, and the diagnostic thresholds that guide clinical decision-making. The broader landscape of geriatric health conditions is covered in the geriatrics reference index.

Definition and scope

Osteoporosis is defined by the World Health Organization as a bone mineral density (BMD) T-score of −2.5 or lower at the femoral neck or lumbar spine, measured by dual-energy X-ray absorptiometry (DXA) (WHO Scientific Group on the Assessment of Osteoporosis, 2004). A T-score between −1.0 and −2.5 is classified as osteopenia, representing below-average bone density that does not yet meet the threshold for full disease diagnosis.

The National Osteoporosis Foundation estimates that 44 million Americans have either osteoporosis or low bone density. Among women age 50 and older, approximately 1 in 2 will experience an osteoporosis-related fracture during their lifetime; among men in the same age group, the figure is approximately 1 in 4 (NOF Clinician's Guide to Prevention and Treatment of Osteoporosis, 2022).

Fracture risk is not solely a function of bone density. The FRAX tool, developed by the University of Sheffield and endorsed by the WHO, integrates 12 clinical risk factors — including age, sex, prior fracture, glucocorticoid use, and parental hip fracture history — to calculate the 10-year probability of a major osteoporotic fracture or hip fracture. This shifts clinical framing from a density-only diagnosis to a probabilistic, multifactorial risk model.

The regulatory and standards context for osteoporosis management intersects with Medicare coverage policy, particularly the Bone Mass Measurement Act (42 U.S.C. § 1395x), which mandates Medicare Part B coverage for DXA screening in qualifying beneficiaries. Additional policy context appears in the regulatory context for geriatrics.

How it works

Bone is continuously remodeled through a cycle of resorption by osteoclasts and formation by osteoblasts. Peak bone mass is typically achieved by the late 20s. After that threshold, resorption begins to outpace formation gradually; in women, the pace accelerates sharply in the 5 to 7 years following menopause due to the loss of estrogen's suppressive effect on osteoclast activity.

Four primary physiological drivers govern bone loss in older adults:

  1. Estrogen and testosterone decline — Estrogen suppresses osteoclast-mediated resorption; its loss after menopause accelerates trabecular bone loss by up to 2–3% per year (NEJM, "Estrogen and Bone," 2005). Testosterone decline in aging men produces a parallel but slower effect.
  2. Calcium and vitamin D insufficiency — Inadequate intake or absorption of calcium and vitamin D impairs mineralization. The Institute of Medicine recommends 1,200 mg of calcium daily and 600–800 IU of vitamin D daily for adults over age 70 (National Academies, Dietary Reference Intakes for Calcium and Vitamin D, 2011).
  3. Secondary causes — Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis, reducing bone formation by suppressing osteoblastogenesis; the American College of Rheumatology published specific prevention guidelines for glucocorticoid-induced bone loss in 2022.
  4. Mechanical unloading — Reduced physical activity and prolonged immobilization decrease the mechanical stimulation that drives osteoblast activity, further tipping the balance toward net bone loss.

Trabecular bone (found in vertebrae and the distal radius) is lost at a faster rate than cortical bone (found in the femoral shaft and tibia), which explains why vertebral compression fractures and wrist fractures are among the earliest fracture types observed in postmenopausal women.

Common scenarios

Three fracture patterns account for the largest share of osteoporosis-related morbidity in geriatric populations:

Hip fracture is the most clinically severe osteoporotic fracture. Mortality within 12 months of a hip fracture in adults over age 65 ranges from 14% to 36% depending on comorbidity burden, with men consistently showing higher mortality than women at equivalent ages (Centers for Disease Control and Prevention, Hip Fractures Among Older Adults). Roughly half of hip fracture survivors do not regain prefracture ambulatory function, linking this event directly to long-term disability and institutionalization.

Vertebral compression fracture (VCF) is the most common osteoporotic fracture type, yet approximately two-thirds of VCFs are asymptomatic at the time of occurrence (American Academy of Orthopaedic Surgeons). When symptomatic, acute back pain, height loss, and progressive kyphosis are the characteristic presentations. Multiple VCFs compound functional limitation and reduce pulmonary capacity by compromising thoracic volume.

Distal radius (wrist) fracture typically results from a fall on an outstretched hand and is often the first sentinel fracture that prompts osteoporosis evaluation in postmenopausal women in their 50s and 60s. It carries lower direct mortality risk than hip fracture but signals elevated systemic fracture risk that warrants formal DXA assessment and FRAX scoring.

The relationship between fall risk and fracture risk is inseparable in geriatric populations. The falls and fall prevention reference covers the fall-specific assessment and intervention framework that complements bone density management.

Decision boundaries

Clinical decision-making in osteoporosis management centers on three discrete thresholds:

Screening initiation: The United States Preventive Services Task Force (USPSTF) recommends DXA screening for all women age 65 and older, and for postmenopausal women under 65 with elevated fracture risk as determined by a validated risk assessment tool (USPSTF Recommendation Statement, 2018). No analogous USPSTF recommendation exists for men, though the National Osteoporosis Foundation and the American College of Physicians recommend DXA for men age 70 and older.

Treatment initiation: The National Osteoporosis Foundation guidelines identify four specific criteria that independently indicate pharmacologic treatment:

  1. Prior hip or vertebral fracture
  2. DXA T-score ≤ −2.5 at the femoral neck, total hip, or lumbar spine
  3. Low bone mass (T-score between −1.0 and −2.5) plus a 10-year FRAX probability ≥ 3% for hip fracture
  4. Low bone mass plus a 10-year FRAX probability ≥ 20% for major osteoporotic fracture

Monitoring interval: For patients on pharmacologic therapy, DXA is typically repeated at 1 to 2 years to assess treatment response; for those not on therapy but with osteopenia, a 2-year interval is standard, though the interval may extend to 5 years in patients with mild bone loss and low clinical risk.

Pharmacologic agents are classified by mechanism. Antiresorptives — including bisphosphonates (alendronate, zoledronic acid), denosumab, and selective estrogen receptor modulators — reduce osteoclast activity. Anabolics — including teriparatide and abaloparatide — stimulate osteoblast activity and are generally reserved for patients with severe osteoporosis or those who have failed antiresorptive therapy. Romosozumab, a sclerostin inhibitor approved by the FDA in 2019, functions as a dual-action agent with both antiresorptive and anabolic properties.

The intersection of osteoporosis with polypharmacy and medication review is clinically significant: bisphosphonate therapy, calcium supplementation, and vitamin D dosing all require reconciliation against existing medication regimens, renal function parameters, and comorbid conditions in older adults managing multiple chronic diseases.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)